GlassScriptPhysician profile
Kevin Rabii
NPI 1326579277
$4,348.87
in general payments reported to CMS, 2019-2025
29 companies · $1,199 in 2025
The $1,199 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,343 · 2023: $990 · 2024: $817 · 2025: $1,199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,693 · Travel and Lodging: $312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,693.31 |
| Travel and Lodging | $312.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $974.30 | 2023-2025 | Mitraclip, Triclip, Amplatzer Amulet |
| Amgen INC. | $582.78 | 2022-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $490.59 | 2022-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor, Watchman Access System |
| Novartis Pharmaceuticals Corporation | $371.59 | 2023-2025 | |
| Medtronic, INC. | $286.95 | 2022-2025 | Corevalve Evolut R, Linq II |
| Boehringer Ingelheim Pharmaceuticals, INC. | $187.00 | 2022-2024 | Jardiance |
| Irhythm Technologies, INC. | $170.31 | 2023-2024 | Zio Xt Patch, Zio Monitor, Zio At Patch |
| E.R. Squibb & Sons, L.L.C. | $150.87 | 2022-2025 | Camzyos |
| Astellas Pharma US INC | $149.22 | 2022 | |
| Alnylam Pharmaceuticals INC. | $125.00 | 2023 | Amvuttra |
| Heartflow, INC. | $121.86 | 2023 | Ffrct |
| Bayer Healthcare Pharmaceuticals INC. | $81.73 | 2022-2024 | |
| Shockwave Medical, INC | $74.85 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $69.08 | 2023-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $61.39 | 2022-2023 | Farxiga |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Medical Corporation | $61.08 | 2022-2023 | Tr Band, Glidesheath Slender, Optitorque |
| Novo Nordisk INC | $46.19 | 2025 | Wegovy |
| Lexicon Pharmaceuticals, INC. | $41.47 | 2024 | |
| Edwards Lifesciences Corporation | $36.33 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $36.16 | 2024 | Verquvo |
| Bridgebio Pharma, INC. | $32.65 | 2025 | Attruby |
| Inspire Medical Systems, INC. | $31.92 | 2025 | Inspire |
| W. L. Gore & Associates, INC. | $26.99 | 2025 | Gore Cardioform Septal Occluder |
| Daiichi Sankyo INC. | $26.88 | 2023 | Injectafer |
| Impulse Dynamics (USA) INC. | $26.21 | 2024 | Optimizer |
| Atricure, INC. | $25.88 | 2023 | |
| Cvrx, INC. | $24.78 | 2024 | Barostim Neo System |
| Pfizer INC. | $18.97 | 2025 | |
| Philips North America LLC | $15.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Rabii listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.